Search Results - "Harrison, Joseph A."

Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument by Tompkins, D. Andrew, Bigelow, George E, Harrison, Joseph A, Johnson, Rolley E, Fudala, Paul J, Strain, Eric C

“…Abstract Introduction The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered scale assessing opioid withdrawal. Though commonly used…”
Get full text

Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential by Reissig, Chad J., Harrison, Joseph A., Carter, Lawrence P., Griffiths, Roland R.

“…Rationale Infrahuman and human studies suggest that a determinant of the abuse potential of a drug is rate of onset of subjective effects. Objectives This…”
Get full text

Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence by Dunn, Kelly E, Harrison, Joseph A, Leoutsakos, Jeannie-Marie, Han, Dingfen, Strain, Eric C

“…Neither the predictive value of early continuous abstinence in alcohol use disorder (AUD) or the point at which this effect may emerge has been evaluated. This…”
Get full text

What is the most cost-effective advertising strategy for alcohol pharmacotherapy clinical trials? by Tompkins, David A, Harrison, Joseph A, Strain, Eric C

Get full text

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone by Tompkins, David Andrew, Lanier, Ryan K., Harrison, Joseph A., Strain, Eric C., Bigelow, George E.

“…Rationale Prescription opioid abuse has risen dramatically in the United States as clinicians have increased opioid prescribing for alleviation of both acute…”
Get full text

Recruitment Techniques for Alcohol Pharmacotherapy Clinical Trials: A Cost-benefit Analysis by Tompkins, D Andrew, Sides, Jessica A, Harrison, Joseph A, Strain, Eric C

“…OBJECTIVES:Alcohol-use disorders (AUDs) represent a large public health burden with relatively few efficacious pharmacotherapies. Randomized controlled trials…”
Get full text

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation by Lanier, Ryan K., Umbricht, Annie, Harrison, Joseph A., Nuwayser, Elie S., Bigelow, George E.

“…Rationale Managed withdrawal (i.e., detoxification) from opioid dependence is a widespread clinical procedure that is a necessary step for those pursuing…”
Get full text

Evaluation of a transdermal buprenorphine formulation in opioid detoxification by Lanier, Ryan K., Umbricht, Annie, Harrison, Joseph A., Nuwayser, Elie S., Bigelow, George E.

“…ABSTRACT Aims  Buprenorphine is marketed in a sublingual formulation for treatment of opioid dependence. A transdermal formulation has been developed that may…”
Get full text

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Soluble-Films by Strain, EC, Harrison, JA, Bigelow, GE

“…A sublingual soluble‐film formulation of buprenorphine/naloxone (B/N) has been approved by the US Food and Drug Administration for the treatment of opioid…”
Get full text

RESEARCH REPORT: Evaluation of a transdermal buprenorphine formulation in opioid detoxification by Lanier, Ryan K, Umbricht, Annie, Harrison, Joseph A, Nuwayser, Elie S, Bigelow, George E

“…Buprenorphine is marketed in a sublingual formulation for treatment of opioid dependence. A transdermal formulation has been developed that may provide…”
Get full text